The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | The outcomes of dara-VTd in patients with treatment-naive systemic AL amyloidosis
Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, discusses the outcomes of patients with treatment-naive systemic light chain (AL) amyloidosis receiving the quadruplet dara-VTd regimen consisting of daratumumab, bortezomib, thalidomide and dexamethasone. Due to concerns around fluid retention, potential cardiac toxicities, and risk of thrombosis, immunomodulatory drugs (IMiDs), such as thalidomide, are administered with caution in patients with AL amyloidosis. Dr Khwaja highlights that, in a cohort of patients in the United Kingdom, encouraging efficacy of the dara-VTd quadruplet was observed, but that clinicians must be mindful of how the therapy is delivered, considering dosing attenuation of thalidomide if necessary. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
